

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14620-0012US1	Application No. 09/622,433
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit 1655

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1						
	2						
	3						
	4						
	5						
	6						
	7						
	8						
	9						
	10						
	11						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	12	WO 98/50048	11/12/1998	WIPO				
	13	WO 99/42125	08/26/1999	WIPO				
	14	1 054 686	05/15/2002	Europe				
	15							
	16							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	17	NUIJEN ET AL., "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agent Aplidine", PDA Journal of Pharmaceutical Science & Technology, vol. 54, no. 3, May/June 2000, pp. 193-208
	18	"Mannitol", Handbook of Pharmaceutical Excipients, Second Edition, Edited by Ainley Wade and Paul J. Weller, 1994, pp. 294-298
	19	
	20	

Examiner Signature /Randall Winston/	Date Considered 11/06/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.W./